Home Biosimilar Antibodies Immunology & Inflammation IL Receptor Talacotuzumab (Anti-IL-3Ra / CD123)
For research use only. Not for use in humans.

Talacotuzumab (Anti-IL-3Ra / CD123)

Synonyms: IL-3RA， CD123

Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD.

Talacotuzumab (Anti-IL-3Ra / CD123)

Quality Control

Batch: A243101 Purity: 99% Protein concentration: 3.3mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD.

Product Details

CAS No. 1826831-79-1
Molecular Weight 146.06 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05995041 NOT_YET_RECRUITING Acute Myeloid Leukemia Shenzhen Geno-Immune Medical Institute 2027-06-30 PHASE1
NCT04318678 RECRUITING Drug: CD123-CAR T|Drug: Cyclophosphamide|Drug: Fludarabine|D AML/MDS; B-ALL; T-ALL; BPDCN St. Jude Children's Research Hospital 2020-07-29 PHASE1
NCT07464951 RECRUITING Drug: Ruxolitinib (JAKAVI®) Acute Myeloid Leukemia (AML) Stephan Grupp MD PhD 2026-05-14 PHASE1
NCT06765876 RECRUITING Leukemia, Myeloid, Acute(AML); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic Syndromes (MDS); Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Institute of Hematology and Blood Transfusion, Czech Republic 2024-10-23 EARLY_PHASE1
NCT03222674 NOT_YET_RECRUITING Acute Myeloid Leukemia Shenzhen Geno-Immune Medical Institute 2026-12-31 PHASE1; PHASE2
NCT04016129 NOT_YET_RECRUITING B-cell Leukemia Shenzhen Geno-Immune Medical Institute 2027-07-01 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-27)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.